Table 3 Change from baseline in 6MWD, BDI scores, WHO functional classification and NT-proBNP levels after ambrisentan treatment (ITT population)
Efficacy measures | Baseline | Week 12 | Week 24 |
|---|---|---|---|
6MWD, meters (LOCF) | |||
N | 133 | 133 | 133 |
Mean (SD) | 377.1 (61.30) | +53.6 (64.50) | +64.4 (91.17) |
*P value (95 % CI) | <0.001 (42.5; 64.7) | <0.001 (48.7; 80.0) | |
BDI scores (LOCF) | |||
N | 133 | 133 | 133 |
Mean (SD) | 2.5 (1.37) | −0.3 (1.52) | −0.2 (1.95) |
P value (95 % CI) | <0.001 | 0.003 | |
WHO functional classification, n (%) (LOCF) | |||
N | - | 133 | 133 |
Improved by class 1/2 | 44 (33.1)/0 | 51 (38.3)/0 | |
No change | 84 (63.2) | 77 (57.9) | |
Worsened by class 1/2 | 4 (3.0)/1 (0.8) | 3 (2.3)/2 (1.5) | |
NT-proBNP levels, ng/L (Observed data) | |||
N | 132 | 123 | 122 |
Mean (SD) | 1600.7 (1832.84) | −861.4 (1452.96) | −806.0 (1384.00) |
P values (95 % CI) | P < 0.001 | P < 0.001 | |